These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19597960)

  • 21. Impact of enzyme replacement therapy on linear growth in Korean patients with mucopolysaccharidosis type II (Hunter syndrome).
    Cho SY; Huh R; Chang MS; Lee J; Kwun Y; Maeng SH; Kim SJ; Sohn YB; Park SW; Kwon EK; Han SJ; Jung J; Jin DK
    J Korean Med Sci; 2014 Feb; 29(2):254-60. PubMed ID: 24550654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey.
    Burton BK; Guffon N; Roberts J; van der Ploeg AT; Jones SA;
    Mol Genet Metab; 2010; 101(2-3):123-9. PubMed ID: 20638311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II.
    Muenzer J; Burton BK; Harmatz P; Gutiérrez-Solana LG; Ruiz-Garcia M; Jones SA; Guffon N; Inbar-Feigenberg M; Bratkovic D; Hale M; Wu Y; Yee KS; Whiteman DAH; Alexanderian D;
    Mol Genet Metab; 2022; 137(1-2):92-103. PubMed ID: 35961250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry.
    Racoma MJC; Calibag MKKB; Cordero CP; Abacan MAR; Chiong MAD
    Orphanet J Rare Dis; 2021 Jul; 16(1):323. PubMed ID: 34289859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points.
    Glamuzina E; Fettes E; Bainbridge K; Crook V; Finnegan N; Abulhoul L; Vellodi A
    J Inherit Metab Dis; 2011 Jun; 34(3):749-54. PubMed ID: 21327479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II.
    Schulze-Frenking G; Jones SA; Roberts J; Beck M; Wraith JE
    J Inherit Metab Dis; 2011 Feb; 34(1):203-8. PubMed ID: 20978944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment.
    Beck M
    Curr Pharm Biotechnol; 2011 Jun; 12(6):861-6. PubMed ID: 21235446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of idursulfase in the treatment of mucopolysaccharidosis II (Hunter syndrome): a post-marketing study in Japan.
    Ueda K; Hokugo J
    Expert Opin Drug Saf; 2020 Jul; 19(7):891-901. PubMed ID: 32342708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized study.
    Muenzer J; Burton BK; Harmatz P; Gutiérrez-Solana LG; Ruiz-Garcia M; Jones SA; Guffon N; Inbar-Feigenberg M; Bratkovic D; Hale M; Wu Y; Yee KS; Whiteman DAH; Alexanderian D;
    Mol Genet Metab; 2022; 137(1-2):127-139. PubMed ID: 36027721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
    Okuyama T; Tanaka A; Suzuki Y; Ida H; Tanaka T; Cox GF; Eto Y; Orii T
    Mol Genet Metab; 2010 Jan; 99(1):18-25. PubMed ID: 19773189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
    Sohn YB; Cho SY; Lee J; Kwun Y; Huh R; Jin DK
    Mol Genet Metab; 2015 Feb; 114(2):156-60. PubMed ID: 25219292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical response to long term enzyme replacement treatment in children, adolescent and adult patients with Hunter syndrome.
    Dalmau Serra J; Vitoria Miñana I; Calderón Fernández R; Cortell Aznar I
    Med Clin (Barc); 2015 Nov; 145(9):392-8. PubMed ID: 26360015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series.
    Lampe C; Bosserhoff AK; Burton BK; Giugliani R; de Souza CF; Bittar C; Muschol N; Olson R; Mendelsohn NJ
    J Inherit Metab Dis; 2014 Sep; 37(5):823-9. PubMed ID: 24596019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.
    Barbier AJ; Bielefeld B; Whiteman DA; Natarajan M; Pano A; Amato DA
    Mol Genet Metab; 2013 Nov; 110(3):303-10. PubMed ID: 23988379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report.
    Muenzer J; Lamsa JC; Garcia A; Dacosta J; Garcia J; Treco DA
    Acta Paediatr Suppl; 2002; 91(439):98-9. PubMed ID: 12572850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hunter syndrome in an 11-year old girl on enzyme replacement therapy with idursulfase: brain magnetic resonance imaging features and evolution.
    Manara R; Rampazzo A; Cananzi M; Salviati L; Mardari R; Drigo P; Tomanin R; Gasparotto N; Priante E; Scarpa M
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S67-72. PubMed ID: 20052546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Home treatment in paediatric patients with Hunter syndrome: the first Italian experience.
    Ceravolo F; Mascaro I; Sestito S; Pascale E; Lauricella A; Dizione E; Concolino D
    Ital J Pediatr; 2013 Sep; 39():53. PubMed ID: 24011228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
    Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
    Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
    Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
    Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.
    Okuyama T; Eto Y; Sakai N; Minami K; Yamamoto T; Sonoda H; Yamaoka M; Tachibana K; Hirato T; Sato Y
    Mol Ther; 2019 Feb; 27(2):456-464. PubMed ID: 30595526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.